<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04266665</url>
  </required_header>
  <id_info>
    <org_study_id>DexProB</org_study_id>
    <nct_id>NCT04266665</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome</brief_title>
  <official_title>Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgia Tsaousi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain tumor surgery is commonly associated with different degrees of preoperative&#xD;
      intracranial hypertension and surrounding tumor edema, elicited by tumor underlying&#xD;
      pathophysiology. During craniotomy for brain tumor resection maintenance of hemodynamic&#xD;
      stability and intracranial homoeostasis is of paramount importance. Disordered hemodynamics&#xD;
      or adverse stress may activate the immune inflammation or neuroendocrine responses and lead&#xD;
      to a surge of inflammatory mediators and stress hormones, which are implicated in secondary&#xD;
      brain insults.&#xD;
&#xD;
      Adverse physiological responses caused by intraoperative disordered hemodynamics or&#xD;
      surgery-related damage, may lead to some secondary brain injury (such as cerebral edema or&#xD;
      cerebral hemorrhage), aggravating damage to brain tissue and affecting the recovery from&#xD;
      anesthesia, cognition and prognosis in patients.&#xD;
&#xD;
      Prevention of secondary brain injury is a key-endpoint to improve clinical outcomes in glioma&#xD;
      patients undergoing craniotomy.&#xD;
&#xD;
      Alpha2-adrenoceptor agonists have been widely used for sedation, analgesia and&#xD;
      anti-sympathetic actions for many years, but the definite evidence of their potential use as&#xD;
      neuroprotectants has so far been confined to animal studies, yet the findings are&#xD;
      inconsistent.&#xD;
&#xD;
      Dexmedetomidine (DEX) has been demonstrated to be a new type a2 adrenergic receptor (a2-AR)&#xD;
      agonist, which can selectively bind with the a1 and a2 adrenergic receptor, and playing a&#xD;
      dual role by restraining the activity of sympathetic nervous and stimulating the vagus nerve.&#xD;
      Dexmedetomidine (DEX) also plays an important role in in inhibiting inflammatory and&#xD;
      neuroendocrine responses. Animal experiments showed that the right must have a&#xD;
      dexmedetomidine neuro-protective effect. However, the brain-protective effect of&#xD;
      dexmedetomidine in anesthesia of craniotomy resection of glioma has not been reported.&#xD;
&#xD;
      Thus, the aim of this study was to explore the effect of dexmedetomidine on perioperative&#xD;
      brain protection, as well as cerebral oxygenation and metabolic status aiming to provide a&#xD;
      basis for clinical rational drug use in patients undergoing craniotomy resection of glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant will receive standard monitoring (ECG, SpO2, SBP, BIS, urine output,&#xD;
      temperature). More detailed hemodynamic monitoring will be obtained by Edwards Lifesciences&#xD;
      ClearSight system (CO, CI, SV, SVI, SVV, SVR, SVRI).&#xD;
&#xD;
      TCI Propofol and Remifentanil will be the agents of choice for induction and maintenance in&#xD;
      anesthesia and cisatracurium will be used for neuromuscular blockade for intubation.&#xD;
&#xD;
      Protective mechanical ventilation will be chosen (7ml/kg IBW) with a respiratory rate to&#xD;
      obtain a PaCO2 of 35-40 mmHg. PEEP will be changed for the best PaO2/FiO2 ratio and FiO2 of&#xD;
      choice will be 0.5.&#xD;
&#xD;
      The radial artery catheterization will be applied for direct blood pressure measurement and&#xD;
      arterial blood gas sampling (pH, PaO2, PaCO2, HCO3, BE, osmolality, lactic acid, Hb, glucose,&#xD;
      Na and K will be measured).&#xD;
&#xD;
      The jugular bulb ipsilateral to the craniotomy site will be catheterized for receiving blood&#xD;
      samples for blood gas analysis. The following oxygenation and metabolic parameters /&#xD;
      derivates will be measured or calculated: SjvO2, pH, PjvO2, PjvCO2, HCO3, BE, Osmolality,&#xD;
      Lactic acid jv, Hb, Glucose, Na, K, AjvDO2, AjvCO2, O2ERbr, eRQbr, AjvDL, and LOI.&#xD;
&#xD;
      Dexmedetomidine or normal saline (placebo) administration will start 10 minutes after&#xD;
      anesthesia induction and maintained throughout the surgical procedure.&#xD;
&#xD;
      Phases&#xD;
&#xD;
        -  T0: 5 minutes before administration of either DEX or placebo&#xD;
&#xD;
        -  T15: 10 minutes after administration of either DEX or placebo&#xD;
&#xD;
        -  T30: 30 minutes after administration of either DEX or placebo&#xD;
&#xD;
        -  T60: 60 minutes after administration of either DEX or placebo&#xD;
&#xD;
        -  T120: 120 minutes after administration of either DEX or placebo&#xD;
&#xD;
        -  T240: 240 minutes after administration of either DEX or placebo&#xD;
&#xD;
        -  End of surgical procedure Blood samples for measuring S-100b, NSE, cortisol, TNF-a and&#xD;
           IL-6 will be obtained at phases T0, end of surgery and 24 hours after administration of&#xD;
           either DEX or placebo.&#xD;
&#xD;
      Neurocognitive testing will be performed before surgery, 1 week and 1 month later using&#xD;
      Karnofsky Performance Status (KFS), Mini Mental State Exam (MMSE), Μontreal Cognitive&#xD;
      Assessment (MoCA) and Addenbrooke's Cognitive Exam (ACE III).&#xD;
&#xD;
      Intraoperative consumption of propofol and remifentanil will also be recorded&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in S-100b protein</measure>
    <time_frame>End of surgical procedure and 24 hours postoperatively</time_frame>
    <description>Alterations in S-100b (μg/L) after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in NSE</measure>
    <time_frame>End of surgical procedure and 24 hours postoperatively</time_frame>
    <description>Alterations in NSE (ng/ml) after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum cortisol</measure>
    <time_frame>End of surgical procedure and 24 hours postoperatively</time_frame>
    <description>Alterations in serum cortisol (μg/dl) levels after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum TNF-a</measure>
    <time_frame>End of surgical procedure and 24 hours postoperatively</time_frame>
    <description>Alterations in serum TNF-a (pg/ml) levels after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum IL-6</measure>
    <time_frame>End of surgical procedure and 24 hours postoperatively</time_frame>
    <description>Alterations in serum IL-6 (pg/ml) levels after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Mini-Mental State Exam (MMSE)</measure>
    <time_frame>1 week and 1 month after the end of surgical procedure</time_frame>
    <description>Alterations in Mini-Mental State Exam (MMSE) after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Μontreal Cognitive Assessment (MoCA)</measure>
    <time_frame>1 week and 1 month after the end of surgical procedure</time_frame>
    <description>Alterations in Μontreal Cognitive Assessment (MoCA) after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Addenbrooke's Cognitive Exam (ACE III)</measure>
    <time_frame>1 week and 1 month after the end of surgical procedure</time_frame>
    <description>Alterations in Addenbrooke's Cognitive Exam (ACE III) after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in jugular venous oxygen saturation</measure>
    <time_frame>10, 30, 60, 120, 240 minutes after commencing the infusion of the tested agent and end of surgical procedure</time_frame>
    <description>Alterations in jugular venous oxygen saturation (%), after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in arterio-jugular oxygen difference (AjvDO2)</measure>
    <time_frame>10, 30, 60, 120, 240 minutes after commencing the infusion of the tested agent and end of surgical procedure</time_frame>
    <description>Alterations in arterio-jugular oxygen difference (AjvDO2 [ml/dl]), after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in arterio-jugular carbon dioxide difference (AjvCO2)</measure>
    <time_frame>10, 30, 60, 120, 240 minutes after commencing the infusion of the tested agent and end of surgical procedure</time_frame>
    <description>Alterations in arterio-jugular carbon dioxide difference (AjvCO2 [mmHg]), after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in brain oxygen extraction ratio (O2Erbr)</measure>
    <time_frame>10, 30, 60, 120, 240 minutes after commencing the infusion of the tested agent and end of surgical procedure</time_frame>
    <description>Alterations in brain oxygen extraction ratio (O2Erbr [%]), after intravenous infusion of equivalent doses of dexmedetomidine or placebo (normal saline)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Brain Tumor</condition>
  <condition>Metabolic Disturbance</condition>
  <condition>Inflammatory Response</condition>
  <condition>Oxygen Deficiency</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (NaCl 0.9%) administration will start 10 minutes after anesthesia induction and maintained throughout the surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexdor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA-PS 1-3 (American Society of Anesthesiologists Physical Status classification)&#xD;
&#xD;
          -  Scheduled for elective or semi-elective craniotomy for brain tumor resection&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of craniotomy at the same site&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Delirious person before surgery&#xD;
&#xD;
          -  Preoperative heart rate (HR) &lt;45 beats/min or second or third degree AV block&#xD;
&#xD;
          -  Treatment with a-methyldopa, clonidine or other a2-adrenergic agonist&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Liver or renal failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgia Tsaousi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aristotle University Of Thessaloniki</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgia Tsaousi, Professor</last_name>
    <phone>+302310994855</phone>
    <email>tsaousig@otenet.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anastasia Nikopoulou, MD</last_name>
    <phone>+302310994862</phone>
    <email>anastasian1991@windowslive.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgia Tsaousi, Professor</last_name>
      <phone>+302310994855</phone>
      <email>tsaousig@otenet.gr</email>
    </contact>
    <contact_backup>
      <last_name>Anastasia Nikopoulou, Dr</last_name>
      <phone>+302310994855</phone>
      <email>anastasian1991@windowslive.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Georgia Tsaousi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>brain oxygenation</keyword>
  <keyword>biomarkers</keyword>
  <keyword>neuroinflammation</keyword>
  <keyword>brain metabolism</keyword>
  <keyword>neurocognitive outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

